Peptilogics is an innovative brand dedicated to developing peptide therapeutics to address serious and life-threatening conditions. Their lead investigational program, PLG0206, specifically focuses on prosthetic joint infections (PJI). Peptilogics understands the impact of PJI on patients' lives, which is why they have created a PJI Support Group called PJI Connect.

This online community serves as a valuable resource, allowing individuals to share experiences and build meaningful connections. Peptilogics encourages patients to participate in clinical trials, as they offer the best opportunity to access investigational therapies before they are commercially available. Clinical trials are designed to evaluate the safety and effectiveness of these therapies, with data being reviewed by regulatory authorities for potential approval.

Patients who do not meet the criteria for clinical trials may be eligible for expanded access, also known as compassionate use, upon request by a treating physician. Peptilogics is committed to continuously evaluating their policies and welcomes inquiries from patients and physicians regarding clinical trial participation. With a strong mission and values, Peptilogics is dedicated to improving the lives of patients through their groundbreaking peptide engineering pipeline